Treatment Patterns, Direct Cost of Biologics, and Direct Medical Costs for Rheumatoid Arthritis Patients: A Real-world Analysis of Nationwide Japanese Claims Data
Open Access
- 1 June 2016
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 38 (6) , 1359-1375.e1
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trialAnnals of the Rheumatic Diseases, 2014
- Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I)Modern Rheumatology, 2013
- Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritisRheumatology, 2012
- A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registryAnnals of the Rheumatic Diseases, 2012
- Lack of Head-to-head Trials and Fair Control ArmsJAMA Internal Medicine, 2012
- The Pathogenesis of Rheumatoid ArthritisNew England Journal of Medicine, 2011
- Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of CareClinical Therapeutics, 2011
- Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexateAnnals of the Rheumatic Diseases, 2008
- Epidemiology of adult rheumatoid arthritisAutoimmunity Reviews, 2005
- Socio-economic consequences of rheumatoid arthritis in the first years of the disease.Rheumatology, 1999